Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ANI Pharma Inc
(NQ:
ANIP
)
61.68
+1.16 (+1.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ANI Pharma Inc
< Previous
1
2
3
Next >
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
June 26, 2024
Via
Benzinga
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
June 25, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
June 24, 2024
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.
Via
InvestorPlace
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
June 24, 2024
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close...
Via
Benzinga
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
April 23, 2024
Via
Benzinga
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
March 05, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 10, 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
March 11, 2024
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
ANI Pharmaceuticals's Earnings Outlook
February 28, 2024
Via
Benzinga
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
February 16, 2024
Via
Benzinga
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
November 08, 2023
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the
Via
Benzinga
Expert Ratings for ANI Pharmaceuticals
October 19, 2023
Via
Benzinga
Analyst Expectations for ANI Pharmaceuticals's Future
September 13, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
August 21, 2023
Via
Benzinga
Where ANI Pharmaceuticals Stands With Analysts
July 21, 2023
Via
Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
August 17, 2023
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.
Via
InvestorPlace
Looking Into ANI Pharmaceuticals's Return On Capital Employed
May 23, 2023
Via
Benzinga
Stocks Reverse Gains Ahead Of Slew Of Inflation Data
May 08, 2023
Stocks are lower this afternoon, as investors await a deluge of inflation data amid a rally for the banking sector.
Via
Talk Markets
Why ANI Pharmaceuticals Stock Is Soaring Today
May 08, 2023
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) Q1 revenues were $106.8 million, +65.6% Y/Y, beating the
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 08, 2023
Via
Benzinga
Earnings Preview For ANI Pharmaceuticals
May 05, 2023
Via
Benzinga
ANI Pharmaceuticals Earnings Perspective: Return On Capital Employed
March 13, 2023
Via
Benzinga
ANI Pharmaceuticals's Return On Capital Employed Overview
December 12, 2022
Via
Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 08, 2023
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
Via
Benzinga
Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch
March 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
March 01, 2023
Via
Benzinga
Organon Stock Scores Market Leadership With Jump To 83 RS Rating
January 17, 2023
Organon sees its Relative Strength Rating reach the 80-plus level.
Via
Investor's Business Daily
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.